| 영문 | autonomic nervous system | 한글 | 자율신경계 |
|---|---|---|---|
| 설명 | 사람의 의지와 관계없이, 침을 흘리거나 소화운동 등과 같은 스스로 조정이 되어 움직이는 신경계이며 여기에는 다음과 같은 두 가지가 있다. 1.교감신경계(sympathetic nervous system)-사람이 위험상태에 이르렀을 경우에 흥분이 되는 자율신경계. 즉 심박수의 증가, 소화기 운동의 감소 등의 일이 이곳을 통해서 일어난다. 교감신경이 흥분되면 교감신경의 말단에서 epinephrine, norepinephrine 등의 물질이 분비되고 이것들에 의해서 말초장기가 변화를 일으킨다. 하지만 장기에 따라서 epinephrine이나 norepinephrine의 수용체를 가지고 있어서 여러 가지 다른 장기의 반응을 볼 수가 있다. 수용체는 다음과 같다. -알파수용체(alpha-receptor): 말초혈관의 수축, 기관지의 수축, 동공의 근육의 수축 -베타1수용체(beta 1-receptor): 심장에 존재하는 수용체, 심장을 빨리 뛰게하는 역할을 한다. -베타2수용체(beta 2-receptor): 혈관의 이완, 기관지의 이완, 즉 각 장기들은 그 장기가 가지고 있는 교감신경의 수용체에 따라 교감신경의 흥분(교감신경 말단에서의 epinephrine의 분비)에 대한 반응이 달라진다(예-교감신경이 흥분시에 beta 1-수용체를 가지고 있는 심장은 빨리 뛰게 된다. 교감신경 흥분시에 동공의 근육이 수축해서 동공의 크기가 커진다) 2.부교감신경계(parasympathetic nervous system)-교감신경과 반대로 작용한다. 즉 사람이 졸리거나 쉴 경우에 흥분한다. 부교감신경이 흥분할 때에는 신경의 말단에서 아세칠콜린의 분비가 일어나고 이것으로 인해서 각 장기의 변화가 일어난다. |
||
| 영문 | TNM staging system | 한글 | 종양병기분류계통 |
|---|---|---|---|
| 설명 | 종양의 병기(stage)를 결정하는 한 방법. T는 Tumor(종양)를 뜻하며 원발병터의 크기, 주위조직으로의 침윤정도 등에 따라 T1, T2, T3, T4(숫자가 높을 수록 주위로 침윤이 많다) 등으로 나눈다. N은 Node(림프절)를 뜻하며 침범된 림프절의 갯수, 크기, 위치 등에 따라 N1, N2, N3 등으로 나눈다. M은 Metastasis(전이)를 뜻하며 원격전이의 유무에 따라 M0, M1 등으로 나눈다. 이상의 방법으로 T, N, M이 결정되면 이들을 조합하여 최종적인 병기를 결정한다. 이렇게 결정된 병기는 치료 방침 결정과 예후 판단에 매우 중요하다. |
||
| 영문 | central nervous system(CNS) | 한글 | 중추신경계 |
|---|---|---|---|
| 설명 | 신경계는 중추신경계와 말초신경계로 분류할 수가 있다. 중추신경계란 뇌와 척수로 구성되어 있는 신경계를 이르는 말이다. 말초신경계란 이 이외의 모든 신경계를 이르는 말이다. |
||
| EDDS | electronic development delivery system |
|---|---|
| EHSDS | experimental health services delivery system |
| HDS | Hamilton Depression Scale; Health Data Services; health delivery system; Healthcare Data Systems; he... |
| IDS | iduronate sulfatase; immune deficiency state; inhibitor of DNA synthesis; integrated delivery system... |
| ODS | organized delivery system; osmotic demyelination syndrome |
| insulin activating factor | <chemical> Activates insulin gene transcription in pancreatic beta cells. Synonym: insaf (05 Dec 1998) |
|---|---|
| insulin allergy | When a person's body has an allergic or bad reaction to taking insulin made from pork or beef or from bacteria, or because the insulin is not exactly the same as human insulin or because it has impurities. The allergy can be of two forms. Sometimes an area of skin becomes red and itchy around the place where the insulin is injected. This is called a local allergy. In another form, a person's whole body can have a bad reaction. This is called a systemic allergy. The person can have hives or red patches all over the body or may feel changes in the heart rate and in the rate of breathing. A doctor may treat this allergy by prescribing purified insulins or by desensitisation. See: desensitisation. (09 Oct 1997) |
| insulin antagonist | Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin. (09 Oct 1997) |
| insulin-antagonizing factor | A principle in extracts of the anterior lobe of the hypophysis that raises the blood sugar and antagonises the action of insulin; purified pituitary growth hormone produces an identical effect. Synonym: insulin-antagonizing factor. (05 Mar 2000) |
| insulin binding | When insulin attaches itself to something else. This can occur in two ways. First, when a cell needs energy, insulin can bind with the outer part of the cell. The cell then can bring glucose (sugar) inside and use it for energy. With the help of insulin, the cell can do its work very well and very quickly. But sometimes the body acts against itself. In this second case, the insulin binds with antibodies. If the insulin is an injected form of insulin and not made by the body, the body sees the insulin as an outside or foreign substance. When the injected insulin binds with the antibodies, it does not work as well as when it binds directly to the cell. (09 Oct 1997) |
| insulin coma treatment | Rarely used treatment of major mental illness by means of hypoglycaemic coma induced by insulin. (05 Mar 2000) |
| insulin c-peptide | <investigation> A blood test which measures the amount of C-peptide in the blood. C-peptide is a byproduct of normal insulin production by the beta cells in the pancreas. Normal values are 0.5 to 3.0 ng/ml. Normal levels indicate that the body is still producing its own insulin. Low levels indicate that the pancreas is producing little or no insulin. Elevations can be seen in cases of insulinomas and islet of Langerhans tumours. (27 Sep 1997) |
| insulin dependent diabetes | A form of diabetes that requires the daily injection of the hormone insulin to maintain normal body chemistry. Avoidance of insulin in these patients will result in a severe metabolic derangement known as diabetic ketoacidosis. (27 Sep 1997) |
| insulin-dependent diabetes mellitus | A chronic condition in which the pancreas makes little or no insulin because the beta cells have been destroyed. The body is then not able to use the glucose (blood sugar) for energy. IDDM usually comes on abruptly, although the damage to the beta cells may begin much earlier. The signs of IDDM are a great thirst, hunger, a need to urinate often, and loss of weight. To treat the disease, the person must inject insulin, follow a diet plan, exercise daily, and test blood glucose several times a day. IDDM usually occurs in children and adults who are under age 30. This type of diabetes used to be known as juvenile diabetes, juvenile-onset diabetes, and ketosis-prone diabetes. (09 Oct 1997) |
| insulin hypoglycaemia test | A test to determine the completeness of vagotomy for peptic ulcer; after the surgical procedure is performed, insulin is administered to cause hypoglycaemia; if vagotomy is complete, the acid output from the stomach following administration of insulin is less than that before insulin administration; if the reverse if true, incomplete vagotomy is likely. Synonym: Hollander test. (05 Mar 2000) |
| insulin infusion systems | Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor. (12 Dec 1998) |
| insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| insulin, isophane | <chemical> An intermediate-acting insulin with an approximate time of onset of 2 hours and duration of action of 24 hours, consisting of bovine or pork insulin reacted with zinc chloride and protamine to form a protein complex with a ratio of free and bound insulin, providing action intermediate between regular insulin and protamine zinc insulin. Pharmacological action: hypoglycaemic agents. Chemical name: Insulin Isophane (12 Dec 1998) |
| insulin, lente | <chemical> Sterile suspension, in a buffered water medium, of insulin modified by the addition of zinc chloride in a manner such that the solid phase of the suspension conisists of a mixture of crystals and amorphous material in a ratio of approximately 7:3. Pharmacological action: hypoglycaemic agents. Chemical name: Insulin zinc (12 Dec 1998) |
| insulin-like activity | A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin. (05 Mar 2000) |